About INKE
INKE is a Healthcare company based in Castellbisbal (Spain) founded in 1980, and was acquired by Keensight Capital in April 2023. Manufacturer of active pharmaceutical ingredients and intermediates. Its chief executive, as recorded, is Antonio Pages. INKE offers products and services including Respiratory APIs, Micronization Services, and CMO Services. Its focus areas include Biopharma Outsourcing, CDMO, Small Molecules & Peptides and API Production. Its legal entity is INKE S.A.
Company details
INKE was founded in 1980 as a wholly-owned subsidiary of Neuraxpharm and is based in Castellbisbal, Spain. Active pharmaceutical ingredients and intermediates are produced by the company, with a focus on respiratory and central nervous system products. These are used in treatments for conditions including asthma, COPD, schizophrenia, hypertension, insomnia, epilepsy, and allergies. Operations center on pharmaceutical manufacturing within the healthcare sector.
- Headquarters Castellbisbal, Spain
- Stage Acquired
- SectorsHealthcare
- Emailβ’β’β’β’β’β’β’β’
- Phoneβ’β’β’β’ β’β’β’β’
- Website inke.es
- Social LinkedIn
- Acquired by Keensight Capital (Apr 2023)
- Legal Name Inke S.A.
- Investors
- Acquired byKeensight Capital
(Apr 2023)
Products & Services of INKE
INKE offers a comprehensive portfolio of products and services, including Respiratory APIs, Micronization Services, and CMO Services.
Develops ingredients for inhalation therapies to treat respiratory conditions effectively.
Provides particle size reduction for pharmaceutical applications and quality assurance.
Offers custom manufacturing of APIs with advanced synthesis and global support.
Investors in INKE
INKE has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Keensight Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Keensight Capital is recognized as a European Growth Buyout investor. | keensightcapital.com | Paris, France |
Investor details for INKE
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of INKE
15 people are tracked at INKE (10 in leadership, 5 in team).
| Name | Role | Group |
|---|---|---|
Antonio Pages | CEO | Leadership |
Arnau Novell | Operations Director (interim) | Leadership |
Miquel Bachs Taberner | CEO | Leadership |
Francesc Matas | Chief Information Officer (cio) | Leadership |
Jakob Rydberg | Chief Financial Officer | Leadership |
Ferran Font | Head Of Analysis - Quality Control | Leadership |
Laura Sánchez Salguero | R&d Director (cso) | Leadership |
Carlos Royo Escriche | Human Resources Director | Leadership |
Joan M. Botana Nuñez | Head Of Quality Assurance-gmp | Leadership |
Víctor Bertran Salmerón | HR Business Partner | Leadership |
Jorge Llorens Noguera | Business Development Manager Latam | Team |
Sergio Rodríguez Ropero | API Synthesis Team Leader | Team |
Paula Menu Mejia | Regulatory Affairs Specialist | Team |
Enric Capdevila Urbaneja | Senior API Synthesis Project Leader | Team |
Marc L. | Process Chemist | Team |
Complete people profiles for INKE
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of INKE
2 dated milestones of INKE across 43 years, from founding to its latest funding, stage changes and deals.
- Founded INKE is founded.
- Exit Acquired by Keensight Capital.
Web traffic of INKE
The website of INKE (inke.es) receives about 1.4K visits a month.
- Monthly visits1.4K
▼ 74.6% vs previous month
Websites whose visitors overlap most with INKE. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| google.com | 100% | 85.8B | #1 | View details |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Inke
Complete news archive for INKE
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about INKE
INKE was founded in 1980.
INKE is headquartered in Castellbisbal, Spain. It is registered at Castellbisbal, Cataluna, Spain.
Antonio Pages is the CEO of INKE, as recorded in our data.
INKE was founded in 1980 as a wholly-owned subsidiary of Neuraxpharm and is based in Castellbisbal, Spain. Active pharmaceutical ingredients and intermediates are produced by the company, with a focus on respiratory and central nervous system products. These are used in treatments for conditions including asthma, COPD, schizophrenia, hypertension, insomnia, epilepsy, and allergies. Operations center on pharmaceutical manufacturing within the healthcare sector.
INKE offers Respiratory APIs, Micronization Services, and CMO Services.
INKE has 1 investor. Key investors include Keensight Capital.
INKE operates through Inke S.A..
Yes. INKE was acquired by Keensight Capital in April 2023.

